Browse by Audience
Skip to content
Papers of the Week
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
Authors
Abstract
Livedoid vasculopathy is a rare, chronic, and recurrent disease with limited effective treatments. Its etiopathogenesis remains incompletely understood. Baricitinib, a selective Janus kinase 1 and 2 inhibitor, has been used to treat rheumatoid arthritis and could reduce the disease severity in patients with livedoid vasculopathy.